| scholarly article | Q13442814 |
| P50 | author | Eric C Seaberg | Q106615434 |
| P2093 | author name string | Lake J | |
| Detre K | |||
| Wiesner R | |||
| Everhart J | |||
| Zetterman R | |||
| Charlton M | |||
| Hoofnagle J | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis | Q27860909 | ||
| Epidemiology of hepatitis C | Q28249543 | ||
| Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. | Q40949702 | ||
| Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome | Q41958799 | ||
| Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia | Q42979955 | ||
| Prospective study of hepatitis C virus infection after orthotopic liver transplantation | Q42982393 | ||
| Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up | Q42985109 | ||
| Long-term outcome of hepatitis C infection after liver transplantation | Q43046814 | ||
| Demographic determinants of hepatitis C virus seroprevalence among blood donors | Q43046823 | ||
| A longitudinal analysis of hepatitis C virus replication following liver transplantation | Q43047520 | ||
| Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease | Q43049022 | ||
| Quantitation of hepatitis C virus RNA in liver transplant recipients | Q43049255 | ||
| Causes of graft loss following liver transplantation for chronic hepatitis C. | Q44132762 | ||
| A proposed system for the nomenclature of hepatitis C viral genotypes | Q57205742 | ||
| Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B | Q71051138 | ||
| Liver transplantation in European patients with the hepatitis B surface antigen | Q72623987 | ||
| Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation | Q73398706 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 823-830 | |
| P577 | publication date | 1998-09-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Predictors of patient and graft survival following liver transplantation for hepatitis C. | |
| P478 | volume | 28 |
| Q28346817 | A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients |
| Q35384561 | A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy |
| Q33342063 | A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation |
| Q43039814 | A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. |
| Q45722529 | Activated T cells and soluble molecules in the portal venous blood of patients with cholestatic and hepatitis C virus-positive liver cirrhosis. Possible promotion of Fas/FasL-mediated apoptosis in the bile-duct cells and hepatocyte injury |
| Q35594900 | Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C |
| Q34048752 | Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus |
| Q43831138 | Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. |
| Q60938455 | Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance |
| Q39887907 | Antihepatitis C virus therapy in liver transplanted patients |
| Q46682644 | Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients |
| Q42996792 | Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. |
| Q45415931 | Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. |
| Q24541565 | Antiviral therapy of HCV in the cirrhotic and transplant candidate |
| Q37630394 | Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation |
| Q47678268 | Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. |
| Q41359138 | Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation |
| Q36750266 | Approach to recurrent hepatitis C following liver transplantation |
| Q35917612 | Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient |
| Q27011871 | Challenges of recurrent hepatitis C in the liver transplant patient |
| Q43571031 | Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999. |
| Q27490521 | Characterization of Virus-Specific T-Cell Immunity in Liver Allograft Recipients with HCV-Induced Cirrhosis |
| Q98612724 | Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge |
| Q24514512 | Clinical significance of hepatitis C virus genotypes |
| Q43040909 | Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. |
| Q45333555 | Comparative analysis of outcome following liver transplantation in US veterans |
| Q44366721 | Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation |
| Q43046773 | Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. |
| Q35088460 | Cost-effectiveness of screening for hepatitis C in Canada |
| Q22299427 | Current management and perspectives for HCV recurrence after liver transplantation |
| Q44117967 | Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation |
| Q45262227 | Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. |
| Q43049477 | Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. |
| Q34170315 | Disease recurrence following liver transplantation |
| Q93140661 | Donor and recipient effects on graft and patient survival |
| Q42228443 | Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. |
| Q37735902 | Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis |
| Q36602497 | Effect of nonviral factors on hepatitis C recurrence after liver transplantation |
| Q37203064 | Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome |
| Q42669385 | Effect of race on outcome of orthotopic liver transplantation: a cohort study |
| Q42028499 | Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. |
| Q34294938 | Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection |
| Q57695982 | Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 |
| Q43038914 | Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. |
| Q35543591 | Factors that influence the severity of recurrent hepatitis c virus following liver transplantation |
| Q39333200 | Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants |
| Q33872304 | Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation |
| Q42982631 | HCV in liver transplantation |
| Q41732518 | HCV-related fibrosis progression following liver transplantation: increase in recent years |
| Q36880485 | Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation. |
| Q37627088 | Hepatitis B and C in African Americans: current status and continued challenges |
| Q34426421 | Hepatitis B and C in the liver transplant recipient: current understanding and treatment |
| Q36382231 | Hepatitis C -- identifying patients with progressive liver injury |
| Q27490388 | Hepatitis C and liver transplantation |
| Q33686173 | Hepatitis C and liver transplantation |
| Q59098576 | Hepatitis C and liver transplantation |
| Q77110599 | Hepatitis C and liver transplantation |
| Q26799924 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment |
| Q35017777 | Hepatitis C in the liver transplant recipient: current understanding and treatment |
| Q34725183 | Hepatitis C infection in liver transplantation |
| Q46589665 | Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis |
| Q38174194 | Hepatitis C recurrence: the Achilles heel of liver transplantation |
| Q91656090 | Hepatitis C treatment in liver transplant setting |
| Q92669678 | Hepatitis C viral infection after liver transplantation |
| Q77092848 | Hepatitis C virus and liver transplantation |
| Q42997081 | Hepatitis C virus genotypes and quasispecies |
| Q35105697 | Hepatitis C virus in the human liver transplantation model |
| Q22299128 | Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact |
| Q36749431 | Hepatitis C virus infection--pathobiology and implications for new therapeutic options |
| Q26853500 | Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy |
| Q36652081 | Hepatitis C virus re-infection: new perspectives |
| Q35214724 | Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? |
| Q34974042 | Hepatitis C virus virology and new treatment targets |
| Q34936115 | Hepatitis C: magnitude of the problem |
| Q33809411 | Hepatitis C: the clinical spectrum of the disease |
| Q33712633 | Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection |
| Q34468871 | Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens |
| Q35594584 | Histology predicts cirrhotic evolution of post transplant hepatitis C |
| Q35572054 | Host and donor risk factors before and after liver transplantation that impact HCV recurrence |
| Q45364028 | Hot-topic debate on hepatitis C virus: the type of immunosuppression matters |
| Q34197528 | Human liver transplantation as a model to study hepatitis C virus pathogenesis |
| Q33871612 | IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens |
| Q42270249 | Identifying the superior measure of rapid fibrosis for predicting premature cirrhosis after liver transplantation for hepatitis C. |
| Q34148593 | Immunopathogenesis of hepatitis C virus in the immunosuppressed host |
| Q34232434 | Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles |
| Q35543610 | Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations |
| Q37970381 | Immunosuppression, liver injury and post-transplant HCV recurrence |
| Q35076852 | Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients |
| Q43643377 | Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. |
| Q35125077 | Impact of donor infections on outcome of orthotopic liver transplantation |
| Q41172899 | Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. |
| Q34936148 | Impact of immunosuppressive therapy on recurrence of hepatitis C. |
| Q26782017 | Impact of new treatment options for hepatitis C virus infection in liver transplantation |
| Q33970328 | Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics |
| Q37222388 | Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review |
| Q79117983 | Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors |
| Q91300949 | Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors |
| Q44243304 | Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma |
| Q45730578 | Induction immunosuppression in hepatitis C virus-infected liver transplant recipients |
| Q36997773 | Inflammation and repair in viral hepatitis C. |
| Q42260788 | Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation |
| Q43034122 | Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation |
| Q42971688 | Initial burst of viremia related to CD8 effector memory T cells after living donor liver transplantation in hepatitis C virus-infected recipients. |
| Q42990367 | Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients |
| Q45474964 | Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease |
| Q26781331 | Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance |
| Q36530402 | Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis |
| Q46085776 | Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? |
| Q34426400 | Late hepatic allograft dysfunction |
| Q89474268 | Liver Transplantation Update: 2014 |
| Q35572066 | Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence |
| Q58704499 | Liver transplantation and hepatitis C |
| Q43037581 | Liver transplantation for hepatitis B and C virus-related cirrhosis: mid-term results |
| Q34120704 | Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data |
| Q42982713 | Liver transplantation from anti-hepatitis C virus-positive donors: our experience |
| Q45710914 | Liver transplantation in hepatitis C virus-related cirrhosis. |
| Q37458352 | Liver transplantation in the ethnic minority population: challenges and prospects |
| Q35543605 | Living donor liver transplantation and hepatitis C. |
| Q35572062 | Living donor liver transplantation in patients with hepatitis C |
| Q36587253 | Living-donor liver transplantation and hepatitis C |
| Q35357054 | Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? |
| Q45405259 | Longer survival of liver transplant recipients with hepatitis virus coinfections |
| Q27477838 | Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens |
| Q35194675 | Major challenges limiting liver transplantation in the United States. |
| Q38174249 | Management of HCV transplant patients with triple therapy |
| Q26781741 | Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review |
| Q36392142 | Management of hepatitis C in liver transplant recipients. |
| Q36788362 | Management of hepatitis C infection after liver transplantation |
| Q38874771 | Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review |
| Q34298333 | Management of recurrent hepatitis C following liver transplantation |
| Q36410574 | Management of recurrent viral hepatitis B and C after liver transplantation |
| Q34779730 | Management of viral hepatitis in liver transplant recipients |
| Q44074214 | Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis |
| Q45402178 | Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. |
| Q82674262 | Morphologic features of hepatitis C recurrence in patients after orthotopic liver transplantation-preliminary analysis of our case observations |
| Q43001148 | Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients |
| Q35543586 | Natural history of hepatitis C and outcomes following liver transplantation |
| Q34093754 | Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future |
| Q45382125 | Natural killer cells in hepatitis C virus recurrence following liver transplantation: what role do they play? |
| Q38109628 | New insights in recurrent HCV infection after liver transplantation |
| Q37015805 | New perspectives for preventing hepatitis C virus liver graft infection |
| Q43047920 | Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation |
| Q38371479 | Occult hepatitis C virus infection and its relevance in clinical practice |
| Q33654989 | Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience |
| Q45713243 | Outcome of orthotopic liver transplantation in patients with hepatitis C. |
| Q43040364 | Outcome of posttransplantation hepatitis C virus disease--is it the host, the virus, or how we modify the host and/or the virus? |
| Q36476188 | Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study |
| Q80223431 | Outcomes in adult and pediatric liver transplantation among various ethnic groups |
| Q42980541 | Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation |
| Q42227943 | Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. |
| Q33870245 | Pathogenesis, diagnosis and management of hepatitis C. |
| Q42998971 | Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation |
| Q27480737 | Performance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNA |
| Q42365178 | Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis |
| Q38497824 | Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus |
| Q35862839 | Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation |
| Q88623175 | Posttransplant muscle mass measured by urinary creatinine excretion rate predicts long-term outcomes after liver transplantation |
| Q33988139 | Pre- and post-transplant treatment of hepatitis C. |
| Q34936216 | Pre-emptive treatment of recurrent hepatitis C infection |
| Q45423741 | Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. |
| Q34271696 | Prevention of fungal and hepatitis virus infections in liver transplantation |
| Q36220172 | Prevention of hepatitis C recurrence after liver transplantation: An update |
| Q36760718 | Racial differences in fibrosis progression after HCV-related liver transplantation. |
| Q40113286 | Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition |
| Q27490867 | Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation : Natural history and predictors of outcome |
| Q33809593 | Recurrence of hepatitis C virus infection after liver transplantation |
| Q44461533 | Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone |
| Q34067825 | Recurrent hepatitis C after liver transplant |
| Q33969819 | Recurrent hepatitis C after liver transplantation |
| Q33888820 | Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues |
| Q34280934 | Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis |
| Q73341064 | Recurrent hepatitis C in transplanted patients: more questions than answers |
| Q36655931 | Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop |
| Q50577208 | Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C recurrence. |
| Q42776118 | Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus |
| Q34936182 | Retransplantation for recurrent hepatitis C. |
| Q35572071 | Retransplantation for recurrent hepatitis C: Positive aspects |
| Q35572073 | Retransplantation for recurrent hepatitis C: The argument against |
| Q36273519 | Review article: hepatitis C virus and calcineurin inhibition after renal transplantation |
| Q38083754 | Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients |
| Q36980754 | Risk factors for hepatitis C recurrence after liver transplantation |
| Q35551279 | Role of adult living donor liver transplantation in patients with hepatitis C |
| Q35540281 | Role of living donor liver transplantation in the treatment of hepatitis C virus infection |
| Q35551214 | Selection of donors for living donor liver transplantation |
| Q37066392 | Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C. |
| Q40629465 | Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation |
| Q36997118 | Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients |
| Q37973516 | Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. |
| Q22305418 | Strategies to reduce hepatitis C virus recurrence after liver transplantation |
| Q33384512 | Study of gene expression profile in liver transplant recipients with hepatitis C virus |
| Q34150039 | Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review |
| Q38804947 | The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council |
| Q83834176 | The clinical consequences of utilizing donation after cardiac death liver grafts into hepatitis C recipients |
| Q43600580 | The effect of recipient hepatitis C virus infection on outcomes following heart transplantation |
| Q35125089 | The impact of advancing donor age on histologic recurrence of hepatitis C infection: The perils of ignored maternal advice |
| Q55692477 | The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation. |
| Q50579734 | The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection. |
| Q35572048 | The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients |
| Q38008075 | The outcome of heart transplantation in hepatitis C-positive recipients. |
| Q33596413 | The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? |
| Q43040318 | The pathogenesis of hepatitis C virus is influenced by cytomegalovirus |
| Q84969873 | The value of C4d deposit in post liver transplant liver biopsies |
| Q36758660 | Therapeutic management of recurrent hepatitis C after liver transplantation |
| Q35543596 | To transplant or not to transplant recurrent hepatitis C and liver failure |
| Q36028318 | Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. |
| Q35672482 | Treatment of hepatitis C in solid organ transplantation |
| Q45710594 | Treatment of hepatitis C virus in the liver transplant recipient |
| Q34984114 | Treatment of patients with hepatitis C and cirrhosis |
| Q50584454 | Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. |
| Q34936164 | Treatment of recurrent hepatitis C. |
| Q35543600 | Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease |
| Q34210752 | Treatment strategies for recurrent hepatitis C after liver transplantation |
| Q36855565 | Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy |
| Q38584271 | Update on the Development of Anti-Viral Agents Against Hepatitis C. |
| Q45282590 | Update on the Management of Hepatitis C in Liver Transplant Recipients |
| Q34170425 | Viral hepatitis A, B, and C. |
| Q42272319 | Viral hepatitis in solid organ transplantation |
| Q34033249 | Viral hepatitis in the liver transplant recipient |
| Q45016250 | Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. |
| Q73534640 | [Fibrogenesis and liver transplantation] |
| Q50574546 | [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. |
| Q78008273 | [Inmunosuppression and liver transplantation in patients with hepatitis C virus infection] |
| Q50585667 | [Management of chronic hepatitis C infection in patients infected with the human immunodeficiency virus: from what we know to what we ignore] |
Search more.